Open Access Research

Factors associated with psychological and behavioral functioning in people with type 2 diabetes living in France

Stephanie Boini12*, Marie-Line Erpelding1, Anne Fagot-Campagna3, Mounir Mesbah4, Judith Chwalow5, Alfred Penfornis67, Vincent Coliche7, Etienne Mollet7, Keith Meadows8 and Serge Briançon12

Author Affiliations

1 Clinical Epidemiology and Evaluation, CIC-EC CIE6 Inserm, University hospital of Nancy, France

2 Nancy University, P. Verlaine - Metz University, Paris - Descartes University, EA 4360 Apemac, Nancy, France

3 Department of Chronic Disease and Injury, Institute for Health Surveillance (InVS), Saint-Maurice, France

4 Theoretical and Applied Statistics Unit, Pierre & Marie Curie University - Paris VI, Paris, France

5 National Federation of the Blind, Baltimore, USA

6 Diabetology - Endocrinology - Nutrition - Metabolism, University Hospital of Besançon, France

7 National Association for Diabetes Networks Coordination (ANCRED), Paris, France

8 DHP Research & Consultancy Limited, Tower Hamlets PCT, London, UK

For all author emails, please log on.

Health and Quality of Life Outcomes 2010, 8:124  doi:10.1186/1477-7525-8-124

Published: 2 November 2010



To identify demographic and clinical factors associated with psychological and behavioral functioning (PBF) in people with type 2 diabetes living in France.


In March 2002, approximately 10,000 adults, who had been reimbursed for at least one hypoglycemic treatment or insulin dose during the last quarter of 2001, received a questionnaire about their health status and PBF (3,646 responders). For this analysis, the 3,090 persons with type 2 diabetes, aged 18-85 years old were selected.

PBF was measured with the adapted version of the Diabetes Health Profile for people with type 2 diabetes. This permitted the calculation of three functional scores - psychological distress (PD), barriers to activity (BA), and disinhibited eating (DE) - from 0 (worst) to 100 (best).


Major negative associations were observed with PBF for microvascular complications (a difference of 6.7 in the BA score between persons with and without microvascular complications) and severe hypoglycemia (difference of 7.9 in the BA score), insulin treatment (-8.5 & -9.5 in the PD & BA scores respectively, as compared to treatment with oral hypoglycemic agents), non-adherence to treatment (-12.3 in the DE score for persons forgetting their weekly treatment), increasing weight (-8.5 & -9.7 in the PD & DE scores respectively, as compared to stable weight), at least one psychiatrist visit in 2001 (-8.9 in the DE score), and universal medical insurance coverage (-7.9 in the PD score) (due to low income).


Prevention and management of microvascular complications or adherence to treatment (modifiable factors) could be essential to preserving or improving PBF among people with type 2 diabetes. A specific approach to type 2 diabetes management may be required in groups with a low socioeconomic profile (particularly people with universal medical insurance coverage), or other non modifiable factors.